Shop by goal
Popular compounds
Research resources
Recently viewed
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io
Cerebrolysin
Pick your pack · how long it lasts
At 210 mg/wk — select pack size
1 × 10-vial pack required for packing — samples add on to any pack
Lab-direct quality — full packs or single-vial samples
Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a batch-linked Certificate of Analysis. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.
Order a full sealed 10-vial research pack for a complete study supply, or add a single-vial sample alongside your pack to trial a new compound first. Same lab, same batch, same verified purity — scaled to whatever your research needs.
What It's Researched For
In plain terms, Cerebrolysin is studied as a brain-protection and recovery peptide, mostly after stroke or injury. Here is what that looks like across the research.
Neuroprotection & recovery
In clinical research it is investigated for helping the brain recover after a stroke or head injury, and it is approved for that use in more than 45 countries.
Memory & dementia
Clinical studies explore whether it supports memory and thinking in dementia, with results compared head-to-head against a standard Alzheimer's medicine.
Brain growth-signal support
Research looks at how its small peptides act like the brain's own growth and survival signals to support nerve cells.
Focus & cognition
Studied for steadier attention and clearer thinking through its broad support of brain-cell health.
Overview
Cerebrolysin is a standardised porcine brain-derived peptide preparation approved in over 45 countries for ischemic stroke, TBI, and dementia - a mixture of low molecular weight neuropeptides that functionally mimic BDNF, NGF, GDNF, and CNTF signalling.
Cerebrolysin is unusual among the peptides on this site: it is not a single defined molecule but a standardised enzymatic hydrolysate of porcine brain tissue. The preparation contains 80% free amino acids and 20% low-molecular-weight neuropeptides (under 10 kDa), and those small peptides carry neurotrophic activity that mimics the major brain growth factors.
Despite the mixture-based composition, Cerebrolysin has a surprisingly strong clinical evidence base. A meta-analysis of nine randomised controlled trials covering 1,879 stroke patients showed NIHSS superiority versus placebo at P < 0.0001. Alzheimer's disease trials reported cognitive improvements comparable to donepezil. It is approved in over 45 countries for ischemic stroke, TBI, and dementia indications.
Cerebrolysin is supplied here as a standardised pharmaceutical preparation (215.2 mg/mL peptide concentrate in aqueous solution) for in-vitro and preclinical research.
Mechanism of Action
Cerebrolysin delivers a mixture of small neurotrophic peptides that activate survival pathways, reduce amyloid processing, and stimulate endogenous neurotrophin production in brain tissue.
Cerebrolysin is a low-molecular-weight fraction of polypeptides from porcine brain - roughly 85% free amino acids plus a peptide-nitrogen fraction - standardised to 215.2 mg/mL. Bornstein et al. (Neurological Sciences, 2018) published a meta-analysis of nine stroke RCTs (N = 1,879) reporting superiority over placebo for early reduction of neurological deficit (Mann-Whitney effect size 0.60, P < 0.0001; number-needed-to-treat 7.7) with safety comparable to placebo. The 2023 Cochrane review of Cerebrolysin in acute ischaemic stroke (Ziganshina et al.) is more cautious, concluding moderate-certainty evidence of probably little-to-no difference in all-cause death. Alzheimer's trials have reported cognitive improvements on standard scales, including head-to-head and combination work alongside donepezil.
Common Questions People Are Asking
What is Cerebrolysin and what is it made of?
Cerebrolysin (FPF-1070) is a standardised low-molecular-weight fraction of polypeptides produced by enzymatic hydrolysis of purified porcine brain proteins - roughly 85% free amino acids plus a smaller bioactive peptide fraction, standardised to 215.2 mg/mL. The peptide fraction is what carries neurotrophic activity mimicking endogenous factors like BDNF, NGF and GDNF. It is supplied for laboratory research only.
Is Cerebrolysin a single peptide or a mixture?
It is a standardised mixture - a defined enzymatic hydrolysate of porcine brain tissue dominated by free amino acids with a low-molecular-weight (<10 kDa) bioactive peptide fraction. The ratios are manufactured to pharmaceutical specifications, so batch-to-batch variability is controlled, even though the product is not a single molecule.
Is Cerebrolysin FDA-approved, and where is it approved?
Cerebrolysin is not FDA-approved in the United States and is sold here strictly as a research compound, not for human use. It is approved and marketed as a medicine in a number of other countries (for example Austria, Germany, China, Russia and South Korea) for indications including stroke, traumatic brain injury and dementia. Legal status varies by jurisdiction.
What does the stroke and dementia research actually show?
The evidence is genuinely mixed, which is worth stating plainly. A 2018 meta-analysis of nine RCTs (N=1,879) reported early reduction of neurological deficit versus placebo, while the more conservative 2023 Cochrane review found moderate-certainty evidence of probably little-to-no difference in all-cause death in acute ischaemic stroke. Alzheimer's trials report cognitive improvements, including combination studies with donepezil. These are research findings, not a treatment claim.
Why use Cerebrolysin instead of individual growth factors like BDNF?
Small recombinant growth factors like BDNF are difficult to deliver to the brain because of their size and blood-brain-barrier exclusion, and they have very short half-lives in circulation. Cerebrolysin's peptide fraction is small enough to act centrally and collectively mimics the activity of several neurotrophic factors, which is why it is used as a tool compound for neurotrophic-signalling research.
How is Cerebrolysin administered in research, and what side effects appear?
It is a ready-to-use aqueous concentrate (215.2 mg/mL) given by IV infusion for larger volumes or IM injection for smaller ones; published stroke protocols describe pulse schedules such as 30 mL daily for around 10 days. Reported side effects are generally mild (transient dizziness, agitation), with clinical contraindications noted in status epilepticus and severe renal impairment. We describe these descriptively from the literature and make no dosing recommendation.
How should Cerebrolysin be stored?
Cerebrolysin is supplied as an aqueous solution rather than a lyophilised powder. Store at 2-8 °C in a refrigerator - do not freeze, as freezing can cause precipitation of the peptide fraction. Protect from light. Once opened, use within the product's specified stability window.
Where can I buy Cerebrolysin?
Right here — Cerebrolysin is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging. Strictly for laboratory research use only — not for human use.
How much does Cerebrolysin cost?
Cerebrolysin pricing is shown live on this page, per pack size — 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $300.
Is Cerebrolysin third-party tested?
Yes. Every Cerebrolysin batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.
How do I buy Cerebrolysin?
Add the Cerebrolysin pack size you need to your cart and check out: enter your shipping details, then choose your payment method — cryptocurrency or card — on the next step. Every order ships with its batch Certificate of Analysis (COA). Cerebrolysin is supplied strictly for laboratory research use only, not for human or veterinary use.
What payment methods can I use to buy Cerebrolysin?
At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.
How fast is shipping, and do you ship worldwide?
Yes — we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $300.
Is it legal to buy Cerebrolysin?
In the United States, Cerebrolysin is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.
Pharmacokinetics
Evidence Tier
Overall: Mixed (human + animal)
Cerebrolysin has a genuinely mixed human evidence base — a positive multi-trial stroke meta-analysis alongside a more cautious Cochrane review, plus dementia trial data. It is an approved medicine in 45+ countries but is NOT FDA-approved; the research-grade preparation supplied here is unapproved laboratory material in the US.
Tier 1 · Human clinical
Source References & Further Reading
Last reviewed: 16 June 2026 · New-U Research Compounds
Key Characteristics
Specifications
About Cerebrolysin: Porcine Brain-Derived Neuropeptide Complex Research Guide
Cerebrolysin occupies an unusual middle ground in peptide research. It is not a single defined compound the way most research peptides are, and it is also not a crude extract - it is a standardised enzymatic hydrolysate of porcine brain tissue (FPF-1070) that has been manufactured to pharmaceutical specifications since the 1970s. The preparation is a low-molecular-weight fraction comprising roughly 85% free amino acids plus a peptide fraction (standardised to 215.2 mg/mL), and that small-peptide fraction carries neurotrophic activity that mimics endogenous factors such as BDNF and NGF.
The clinical evidence base is comparatively rich for a mixture product, and it is genuinely mixed - which is the honest research picture. The stroke meta-analysis (Bornstein et al., Neurological Sciences, 2018) covers 1,879 patients across nine RCTs and reports early neurological-deficit benefit over placebo, while the more conservative 2023 Cochrane review (Ziganshina et al.) found moderate-certainty evidence of probably little-to-no difference in all-cause death in acute ischaemic stroke. Alzheimer's datasets include head-to-head and combination work alongside donepezil. That spread of comparative data makes Cerebrolysin a useful reference compound for studying peptide-based neurotrophic interventions.
New-U Research Compounds supplies Cerebrolysin as a pharmaceutical-grade aqueous concentrate (215.2 mg/mL) strictly for in-vitro and laboratory research use. Cerebrolysin is not FDA-approved in the United States, though it is approved and marketed in a number of other countries. Note the clinical contraindications reported in status epilepticus and severe renal impairment. Nothing on this page is medical advice or a dose recommendation, and Cerebrolysin should not replace any prescribed treatment.
Customer Reviews
No customer reviews yet — be the first to share your experience.
More in Cognitive / Neuro
Cerebrolysin vs related Cognitive / Neuro compounds
Descriptive catalog comparison for research sourcing decisions — not dosing guidance. All compounds are for laboratory research use only.